Mice were treated by Nrp1-blocking antibodies: anti-Nrp1a, which blocks binding of semaphorins, and anti-Nrp1b, which blocks binding of Vegfa (Genentech, 10 mg/kg) by intraperitoneal injection, two times per week during 15 days as described previously for tumor models (14, 26). The antibodies were generated and provided by Genentech.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.